From the $800 million pill - Me too!

MedGenMed Medscape General Medicine

Volumn 6, Issue 2, 2004, Pages

  Goozner, Merrill ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIULCER AGENT; BLOOD CLOTTING FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPHENHYDRAMINE; ERYTHROPOIETIN; FLUOXETINE; GENERIC DRUG; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLIN G; POLIOMYELITIS VACCINE; PROPRANOLOL; RANITIDINE; SEROTONIN UPTAKE INHIBITOR; STREPTOMYCIN; SULFAMIDOCHRYSOIDINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VASODILATOR AGENT;

ARTICLE; CARCINOGENICITY; CLINICAL TRIAL; COMPETITION; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG FATALITY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; GASTROINTESTINAL DISEASE; HEART DISEASE; HUMAN; HYPERTENSION; NONHUMAN; PATENT; PHARMACEUTICAL CARE; RHEUMATIC FEVER; SCARLET FEVER; STREPTOCOCCUS INFECTION;

EID: 25144496591     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. The best account I've found of the so-called Prontosil affair is contained in Frank Ryan, Forgotten Plague. See esp. pp. 98-120.
2. Milton Silverman and Philip R. Lee, Pills, Profits, and Politics, p. 86.
3. Peter Temin, "Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry," Bell Journal of Economics 10, no. 2 (1979): 429-46.
4. See also Jane S. Smith, Patenting the Sun: Polio and the Salk Vaccine.
5. Temin, "Technology, Regulation, and Market Structure," p. 438.
6. Richard Harris, The Real Voice, p. 8.
7. Ibid. p. 79.
8. Silverman and Lee, Pills, Profits, and Politics, p. 4-5.
9. Victor R. Fuchs and Harold C. Sox Jr., "Physicians' Views of the Relative Importance Of Thirty Medical Innovations," Health Affairs 20 (Sept./Oct. 2001): 35.
10. David A. Kessler, Janet L. Rose, Robert J. Temple, Renie Schapiro, and Joseph P. Griffin, "Therapeutic-Class Wars: Drug Promotion in a Competitive Marketplace," The New England Journal of Medicine, Nov. 17, 1994, pp. 1350-53.
11. NIH, NIH Contributions to Pharmaceutical Development, Case Study Analysis of the Top-Selling Drugs, Office of Science Policy, Feb. 2000.
12. Interview with George Sachs, Mar. 29, 2001.
13. David Blumenthal et al., "Participation of Life-Science Faculty in Research Relationships with Industry," New England Journal of Medicine, Dec. 5, 1996, pp. 1934-39. Blumenthal and his colleagues asked more than two thousand teaching physicians about their relationships with industry and their publishing habits. Less than a third took money from industry. Scientists funded partially by industry published just as often as their publicly funded colleagues, except for the minority who took more than two-thirds of their money from industry. That minority published less often, were more likely to withhold information from colleagues, and were more likely to have generated trade secrets for their patrons.
14. Kevin Parent, Postgraduate Medicine 96 (Nov. 1, 1994): 53.
15. Henry J. Kaiser Family Foundation, "Prescription Drug Trends," Nov. 2001.
16. NIH, NIH Contributions to Pharmaceutical Development, pp. 12-13.
17. Gardiner Harris, "Prilosec's Maker Switches Users To Nexium, Thwarting Generics," Wall Street Journal, June 6, 2002.
18. Sachs interview.
19. Harris, "Prilosec's Maker."
20. Stephen Hall, "The Claritin Effect: Prescription for Profit," New York Times Magazine, Mar. 11, 2001.
21. Gardiner Harris, "As Blockbuster Claritin Goes Generic, Schering-Plough Pushes a Close Sibling," Wall Street Journal, Mar. 21, 2002.
22. See also Scott Hensley, "More Than Ads, Drug Makers Rely on Sales Representatives," Wall Street Journal, Mar. 14, 2002.
23. Andrew Pollack, "Battling Searle, University Gets Broad Patent for New Painkiller," New York Times, Apr. 12, 2000.
24. Gardiner Harris, "When Its Patents Expired, Merck Didn't Merge - It Found New Drugs," Wall Street Journal, Jan. 10, 2001.
25. Pharmaceutical Research and Manufacturers Association, "Pharmaceutical Industry Honors Discoverers of Celebrex," press release, Mar. 25, 2002. Numerous studies in the academic literature have shown that Cox-2 inhibitors are no better than ibuprofen, diclofenac, and naproxen sodium for reducing aches and pains;
26. see, for instance, A.J. Matheson and D.P. Figgitt, "Rofecoxib: A Review of Its Use in the Management of Osteoarthritis, Acute pain and Rheumatoid Arthritis," Drugs, 61, no. 6 (2001): 833-65;
27. see also R. Hawel et al., "Comparison of the Efficacy and Tolerability of Dexibuprofen and Celecoxib in the Treatment of Osteoarthritis of the Hip," International Journal of Clinical Pharmacology and Therapeutics 4 (Apr. 2003): 153-64.
28. See for instance the special supplement to the American Journal of Medicine, Mar. 30, 1998.
29. Elizabeth Neus, "New Arthritis Relief: Pain-Killers Promise to Be Tummy-Friendly," Chicago Sun-Times, Oct. 28, 1998.
30. "Conquering Pain," Business Week, Mar. 1, 1999, p. 104.
31. "FDA Approves Pain Reliever with Fewer Side Effects," Washington Post, May 22, 1999.
32. Centers for Disease Control and Prevention, National Vital Statistics Report 47 (June 30, 1999);
33. Susan Levenstein et al., "Stress and Peptic Ulcer Disease," Journal of the American Medical Association, Jan. 6, 1999;
34. T.M. MacDonald et al., "Association of Upper Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs with Continued Exposure: Cohort Study," British Medical Journal, Nov. 22, 1997.
35. David R. Lichtenstein and M. Michael Wolfe, "COX-2-selective NSAIDS: New and Improved?" The Journal of the American Medical Association, Sept. 13, 2000, pp. 1297-99.
36. Garret A. FitzGerald and Carlo Patrono, "The Coxibs, Selective Inhibitors of Cyclooxygenase-2," The New England Journal of Medicine, Aug. 9, 2001, pp. 433-42.
37. Melody Petersen, "Doubts Are Raised on the Safety of Two Popular Arthritis Drugs," New York Times, May 22, 2001.
38. FDA, "FDA Approves New Indication and Label Changes for the Arthritis Drug, Vioxx," press release, Apr. 11, 2002.
39. Susan Okie, "Missing Data on Celebrex: Full Study Altered Picture of Drug," Washington Post, Aug. 5, 2001.
40. Peter Jüni, Anne Rutjes, and Paul Dieppe, "Are Selective Cox-2 Inhibitors Superior to Traditional Nonsteroidal Anti-inflammatory Drugs?" British Medical Journal, June 1, 2002, pp. 1287-88.
41. Henry J. Kaiser Family Foundation, "Prescription Drug Trends: A Chartbook Update," Nov. 2001, p. 31.
42. Marcia Angell, "The Pharmaceutical Industry: To Whom Is It Accountable?" The New England Journal of Medicine, June 22, 2000, p. 1904.